 | • レポートコード：MRC2211A104 • 出版社/出版日：Transparency Market Research / 2022年8月 • レポート形態：英文、PDF、160ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トレンスペアレンシーマーケットリサーチ社の当調査レポートでは、世界のてんかん治療薬市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、製品別（第一世代てんかん治療薬、第二世代てんかん治療薬、第三世代てんかん治療薬）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を掲載しています。なお、当書には、Pfizer, Inc.、UCB S.A.、Bausch Health Companies Inc.、Novartis AG、GlaxoSmithKline plc.、Teva Pharmaceutical Industries Ltd.、Sunovion Pharmaceuticals Inc.、Eisai Co., Ltd.、Upsher-Smith Laboratories, LLC.、Amneal Pharmaceuticals LLC.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場見通し ・世界のてんかん治療薬市場規模：製品別 - 第一世代てんかん治療薬の市場規模 - 第二世代てんかん治療薬の市場規模 - 第三世代てんかん治療薬の市場規模 ・世界のてんかん治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のてんかん治療薬市場規模：地域別 - 北米のてんかん治療薬市場規模 - ヨーロッパのてんかん治療薬市場規模 - アジア太平洋のてんかん治療薬市場規模 - 中南米のてんかん治療薬市場規模 - 中東・アフリカのてんかん治療薬市場規模 ・競争状況 |
Epilepsy Therapeutics Market – Scope of Report
TMR’s report on the global epilepsy therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global epilepsy therapeutics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global epilepsy therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the epilepsy therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global epilepsy therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global epilepsy therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global epilepsy therapeutics market.
The report delves into the competitive landscape of the global epilepsy therapeutics market. Key players operating in the global epilepsy therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global epilepsy therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market epilepsy therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Epilepsy Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Epilepsy Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Pipeline
5.2. Epidemiology of Epilepsy
5.3. Key Industry Events
6. Global Epilepsy Therapeutics Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. First Generation Epilepsy Therapeutics
6.3.2. Second Generation Epilepsy Therapeutics
6.3.3. Third Generation Epilepsy Therapeutics
6.4. Market Attractiveness, by Product
7. Global Epilepsy Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel
8. Global Epilepsy Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Epilepsy Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2017–2031
9.2.1. First Generation Epilepsy Therapeutics
9.2.2. Second Generation Epilepsy Therapeutics
9.2.3. Third Generation Epilepsy Therapeutics
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Epilepsy Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. First Generation Epilepsy Therapeutics
10.2.2. Second Generation Epilepsy Therapeutics
10.2.3. Third Generation Epilepsy Therapeutics
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Epilepsy Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. First Generation Epilepsy Therapeutics
11.2.2. Second Generation Epilepsy Therapeutics
11.2.3. Third Generation Epilepsy Therapeutics
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Epilepsy Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. First Generation Epilepsy Therapeutics
12.2.2. Second Generation Epilepsy Therapeutics
12.2.3. Third Generation Epilepsy Therapeutics
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Epilepsy Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. First Generation Epilepsy Therapeutics
13.2.2. Second Generation Epilepsy Therapeutics
13.2.3. Third Generation Epilepsy Therapeutics
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2018)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. UCB S.A.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Bausch Health Companies Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Novartis AG
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. GlaxoSmithKline plc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Sunovion Pharmaceuticals Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Eisai Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Upsher-Smith Laboratories, LLC.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Amneal Pharmaceuticals LLC.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
Table 01: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 06: North America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 09: Europe Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 12: Asia Pacific Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Latin America Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 18: Middle East & Africa Epilepsy Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031